CA3103531A1 - Anti-il36r antibodies - Google Patents

Anti-il36r antibodies Download PDF

Info

Publication number
CA3103531A1
CA3103531A1 CA3103531A CA3103531A CA3103531A1 CA 3103531 A1 CA3103531 A1 CA 3103531A1 CA 3103531 A CA3103531 A CA 3103531A CA 3103531 A CA3103531 A CA 3103531A CA 3103531 A1 CA3103531 A1 CA 3103531A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3103531A
Other languages
English (en)
French (fr)
Inventor
Jeanette Fairhurst
Elena Garnova
William Olson
Sokol Haxhinasto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CA3103531A1 publication Critical patent/CA3103531A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3103531A 2018-07-16 2019-07-16 Anti-il36r antibodies Pending CA3103531A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862698482P 2018-07-16 2018-07-16
US62/698,482 2018-07-16
US201962846989P 2019-05-13 2019-05-13
US62/846,989 2019-05-13
US201962866028P 2019-06-25 2019-06-25
US62/866,028 2019-06-25
PCT/US2019/041952 WO2020018503A2 (en) 2018-07-16 2019-07-16 Anti-il36r antibodies

Publications (1)

Publication Number Publication Date
CA3103531A1 true CA3103531A1 (en) 2020-01-23

Family

ID=67480435

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3103531A Pending CA3103531A1 (en) 2018-07-16 2019-07-16 Anti-il36r antibodies

Country Status (13)

Country Link
US (3) US11267893B2 (https=)
EP (1) EP3823989A2 (https=)
JP (1) JP7386224B2 (https=)
KR (1) KR102895164B1 (https=)
CN (1) CN112513091B (https=)
AU (1) AU2019306217B2 (https=)
BR (1) BR112020027015A2 (https=)
CA (1) CA3103531A1 (https=)
IL (1) IL280013B1 (https=)
MX (2) MX2021000566A (https=)
PH (1) PH12020552178A1 (https=)
SG (1) SG11202012360YA (https=)
WO (1) WO2020018503A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168542A1 (en) 2015-04-15 2016-10-20 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (il-36r)
CA3093692A1 (en) 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis
MX2021000566A (es) 2018-07-16 2021-06-23 Regeneron Pharma Anticuerpos anti-il36r.
EP4182022A1 (en) 2020-07-17 2023-05-24 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for the treatment of neutrophilic dermatoses
JP2023536851A (ja) 2020-07-30 2023-08-30 アナプティスバイオ インコーポレイティッド 魚鱗癬のための抗インターロイキン３６受容体（ｉｌ－３６ｒ）療法
WO2022026829A1 (en) 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity
CN112094349B (zh) * 2020-11-04 2021-02-09 上海华奥泰生物药业股份有限公司 靶向于白介素36r的抗体及其制备方法和应用
EP4289863A4 (en) * 2020-12-17 2025-04-09 Shanghai Huaota Biopharmaceutical Co., Ltd. BISPECIFIC ANTIBODY AGAINST IL-17A AND IL-36R AND USE THEREOF
WO2022150642A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa
WO2022150644A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for acne
WO2022166977A1 (zh) * 2021-02-08 2022-08-11 上海普铭生物科技有限公司 抗人il-36r抗体及其应用
CA3209006A1 (en) * 2021-03-04 2022-09-09 Boehringer Ingelheim International Gmbh Methods for the treatment of gpp
WO2022192531A2 (en) 2021-03-12 2022-09-15 Boehringer Ingelheim International Gmbh Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
CN117480183A (zh) * 2021-06-18 2024-01-30 正大天晴药业集团股份有限公司 抗il-36r抗体及其用途
EP4370550A1 (en) * 2021-07-12 2024-05-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-36 inhibitors for the treatment of netherton syndrome
US20250120374A1 (en) * 2021-10-25 2025-04-17 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric genes
TW202323293A (zh) * 2021-10-29 2023-06-16 新加坡商創響私人有限公司 新型抗ｉｌ－３６ｒ抗體
CN115724975A (zh) 2022-10-20 2023-03-03 江苏荃信生物医药股份有限公司 抗人白介素36受体单克隆抗体及其应用
CN116574189A (zh) * 2023-01-30 2023-08-11 北京智仁美博生物科技有限公司 针对人il-36r和/或人il-1r3的多种抗体及其用途
JP2026506716A (ja) 2023-02-21 2026-02-25 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 Ｉｌ－３６ｒ結合タンパク質及びその医薬的使用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5693489A (en) 1984-03-30 1997-12-02 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US6239268B1 (en) 1994-09-09 2001-05-29 Neurocrine Biosciences, Inc. Interleukin-1 type 3 receptors
JPH10508743A (ja) 1994-09-09 1998-09-02 ニューロクライン バイオサイエンシーズ， インコーポレイテッド インターロイキン−１ タイプ３レセプター
US6326472B1 (en) 1997-10-15 2001-12-04 Schering Corporation Human receptor proteins; related reagents and methods
WO1999019480A2 (en) 1997-10-15 1999-04-22 Schering Corporation Human receptor proteins; related reagents and methods
US20060003323A1 (en) 2000-03-01 2006-01-05 John Alsobrook Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6900016B1 (en) 2000-09-08 2005-05-31 Applera Corporation Polymorphisms in known genes associated with inflammatory autoimmune disease, methods of detection and uses thereof
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20030170630A1 (en) 2000-12-21 2003-09-11 Alsobrook John P. Proteins and nucleic acids encoding same
WO2005100604A2 (en) 2004-04-01 2005-10-27 Sequenom, Inc. Methods for identifying risk of osteoarthritis and treatments thereof
WO2005108415A2 (en) 2004-04-30 2005-11-17 Biogen Idec Ma Inc. Membrane associated molecules
CA2625403A1 (en) 2005-10-17 2007-04-26 Institute For System Biology Tissue-and serum-derived glycoproteins and methods of their use
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
KR102038310B1 (ko) 2011-11-16 2019-11-01 베링거 인겔하임 인터내셔날 게엠베하 항 ｉｌ-36ｒ 항체
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
WO2014144666A2 (en) * 2013-03-15 2014-09-18 The University Of Chicago Methods and compositions related to t-cell activity
WO2016168542A1 (en) * 2015-04-15 2016-10-20 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (il-36r)
JP2020512344A (ja) 2017-03-27 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体併用治療
AU2019234478A1 (en) 2018-03-14 2020-08-20 Boehringer Ingelheim International Gmbh Use of anti-IL36R antibodies for treatment of inflammatory bowel disease
CA3093692A1 (en) 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis
MX2021000566A (es) 2018-07-16 2021-06-23 Regeneron Pharma Anticuerpos anti-il36r.
IL278267B2 (en) 2018-07-16 2025-02-01 Regeneron Pharma Non-human animal models of DITRA disease and their uses

Also Published As

Publication number Publication date
PH12020552178A1 (en) 2021-06-28
SG11202012360YA (en) 2021-01-28
WO2020018503A2 (en) 2020-01-23
AU2019306217B2 (en) 2024-01-25
US20220162326A1 (en) 2022-05-26
CN112513091B (zh) 2024-08-27
WO2020018503A3 (en) 2020-02-20
KR20210032401A (ko) 2021-03-24
JP2021530229A (ja) 2021-11-11
MX2021000566A (es) 2021-06-23
JP7386224B2 (ja) 2023-11-24
US12060428B2 (en) 2024-08-13
US20250011442A1 (en) 2025-01-09
KR102895164B1 (ko) 2025-12-04
IL280013A (en) 2021-03-01
US11267893B2 (en) 2022-03-08
EP3823989A2 (en) 2021-05-26
MX2025007735A (es) 2025-08-01
CN112513091A (zh) 2021-03-16
BR112020027015A2 (pt) 2021-04-06
NZ771227A (en) 2024-04-26
AU2019306217A1 (en) 2021-01-14
IL280013B1 (en) 2026-01-01
US20200017592A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
US12060428B2 (en) Anti-IL36R antibodies
JP7278355B2 (ja) ヒトｉｌ－２３抗原結合タンパク質
JP6797111B2 (ja) イヌｐｄ−ｌ１と結合するｐｄ−ｌ１抗体
JP2021191779A (ja) イヌインターロイキン４受容体アルファに対する抗体
JP5941049B2 (ja) ヒトｔｗｅａｋに対する抗体およびその使用
JP2021530229A5 (https=)
CN115397852B (zh) 工程化抗il-2抗体
KR20120102623A (ko) 조작된 항－ｔｓｌｐ 항체
WO2017205377A2 (en) Compositions and methods for antibodies targeting staphylococcal leukotoxins
US20190040156A1 (en) ANTI-TNF- / ANTI-IL-23 IgG BISPECIFIC ANTIBODIES
TW202134269A (zh) 包含靶向ＴＮＦα及ＩＬ－２３之免疫球蛋白單可變結構域的多肽
JP7307720B2 (ja) Ｉｌ－５抗体、その抗原結合フラグメント、およびそれらの医薬適用
AU2019236822A1 (en) GIPR antibody and GLP-1 fusion protein thereof, and pharmaceutical composition and application thereof
JP2020508074A (ja) Ｃｘｃｒ２抗体及びその使用
EA049652B1 (ru) Антитела к il36r
US20250277029A1 (en) Cannabinoid type 1 receptor binding proteins and uses thereof
US20250197514A1 (en) ANTIBODIES AND IgG FUSION PROTEINS WITH AN EXTENDED HALF-LIFE
RU2800370C2 (ru) Антитело к gipr и его слитый с glp-1 белок, а также фармацевтическая композиция на его основе и его применение
JP2026513302A (ja) 抗ｉｌ－２５抗体及びその使用方法
WO2022262828A1 (zh) 抗il-36r抗体及其用途
HK40110084A (zh) 具有延长的半衰期的抗体和igg融合蛋白
HK1177469B (en) Human il-23 antigen binding proteins
HK1186195B (en) Antibodies against human tweak and uses thereof

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241003

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241003

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241011

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241015

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20241015

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20241015

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250331

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250507

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250625

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250917

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251210

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260327

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260331

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260331

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260331